Macoven Pharmaceuticals

Manufacturer Details

There are currently no manufacturer details available.

Macoven Pharmaceuticals Drugs

V-cof

V-cof

V-COF Suspension: Administer the recommended dose up to four times daily.

CHILDREN

Over 12 years of age - 5 to 10 mL (1 to 2 teaspoonfuls);6 to 12 years of age - 5 mL (1 teaspoonful);2 to 6 years of age - 2.5 mL (1/2 teaspoonful);Under 2 years of age - Consult a physician.

Each 5 mL of V-COF Suspension contains: 6 mg Brompheniramine Maleate, 10 mg Phenylephrine HCl and 25 mg Carbetapentane Citrate in a suspension.

Note: The Hydrochloride salt of Phenylephrine, the Maleate salt of Brompheniramine, and the Citrate salt of Carbetapentane are provided by means of a patented manufacturing process.
Cardec Dm

Cardec Dm

Do not exceed recommended dosage.
Children 6 to under 12 years of age: 1 dropperful (1 mL) every 4 to 6 hours, not to exceed 6 dropperfuls in 24 hours or as directed by a doctor Children under 6 years of age: Consult a doctor
Pyril Dm

Pyril Dm

take every 6 to 8 hours do not take more than 4 doses in 24 hours or as directed by a doctor Adults and children 12 years of age and older 1 to 2 teaspoonsful Children 6 to under 12 years of age 1 teaspoonful Children under 6 years of age Ask a doctor
Bp8 Cough

Bp8 Cough

take every 8 hours do not take more than 3 doses in 24 hours or as directed by a doctor Adults and children 12 years of age and older 2 teaspoonsful Children 6 to under 12 years of age 1 teaspoonful Children under 6 years of age Ask a doctor
Brompheniramine Phenyle...

Brompheniramine Phenylephrine Dm

Do not exceed recommended dosage.
Adults and children 12 years of age and over: 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 6 teaspoonfuls in 24 hours, or as directed by a doctor Children 6 to under 12 years of age: 1/2 teaspoonful (2.5 mL) every 4 to 6 hours, not to exceed 3 teaspoonfuls in 24 hours, or as directed by a doctor Children under 6 years of age: Consult a doctor
Brompheniramine Pseudoe...

Brompheniramine Pseudoephedrine Dm

Do not exceed recommended dosage.
Adults and children 12 years of age and over: 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 6 teaspoonfuls in 24 hours, or as directed by a doctor Children 6 to under 12 years of age: 1/2 teaspoonful (2.5 mL) every 4 to 6 hours, not to exceed 3 teaspoonfuls in 24 hours, or as directed by a doctor Children under 6 years of age: Consult a doctor
Pyril D

Pyril D

take every 6 hours do not take more than 4 doses in 24 hours or as directed by a doctor Adults and children 12 years of age and older 1 to 2 teaspoonsful Children 6 to under 12 years of age 1 teaspoonful Children under 6 years of age Ask a doctor
Trip-pse

Trip-pse

take every 6 hours do not take more than 4 doses in 24 hours or as directed by a doctor do not give more than directed or exceed the recommended daily dosage Adults and children 12 years of age and over 2.67 mL Children 6 to under 12 years of age 1.33 mL Children under 6 years of age Ask a Doctor
Chlordiazepoxide Hydroc...

Chlordiazepoxide Hydrochloride And Clidinium Bromide

Because of the varied individual responses to tranquilizers and anticholinergics, the optimum dosage of Chlordiazepoxide HCl and Clidinium Bromide Capsules varies with the diagnosis and response of the individual patient. The dosage, therefore, should be individualized for maximum beneficial effects. The usual maintenance dose is 1 or 2 capsules, 3 or 4 times a day administered before meals and at bedtime.

Geriatric Dosing

Dosage should be limited to the smallest effective amount to preclude the development of ataxia, oversedation or confusion. The initial dose should not exceed 2 Chlordiazepoxide HCl and Clidinium Bromide Capsules per day, to be increased gradually as needed and tolerated.
Cardec

Cardec

Do not exceed recommended dosage.
Children 6 to under 12 years of age: 1 dropperful (1 mL) every 4 to 6 hours, not to exceed 6 dropperfuls in 24 hours or as directed by a doctor Children under 6 years of age: Consult a doctor
Brompsedm Cough

Brompsedm Cough

take every 4 hours do not take more than 4 doses in 24 hours or as directed by a doctor Adults and children 12 years of age and older 2 teaspoonsful Children 6 to under 12 years of age 1 teaspoonful Children 4 to under 6 years of age 1/2 teaspoonful
Do Not Use in Children under 4 years of age
Spinosad Suspension

Spinosad Suspension

For topical use only. Spinosad Topical Suspension is not for oral, ophthalmic, or intravaginal use.

Shake bottle well. Apply sufficient Spinosad Topical Suspension to cover dry scalp, then apply to dry hair. Depending on hair length, apply up to 120 mL (one bottle) to adequately cover scalp and hair. Leave on for 10 minutes, then thoroughly rinse off Spinosad Topical Suspension with warm water. If live lice are seen 7 days after the first treatment, a second treatment should be applied. Avoid contact with eyes.
Isometheptene Mucate

Isometheptene Mucate

Do not exceed the recommended dosage because severe liver damage may occur.

Tell your doctor about all usage of pain relievers.

FOR RELIEF OF MIGRAINE HEADACHE

The usual adult dosage is two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules within a twelve hour period.

FOR RELIEF OF TENSION HEADACHE

The usual adult dosage is one or two capsules every four hours up to 8 capsules a day.
Nodolor

Nodolor

Do not exceed the recommended dosage because severe liver damage may occur.

Tell your doctor about all usage of pain relievers.

FOR RELIEF OF MIGRAINE HEADACHE

The usual adult dosage is two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules within a twelve hour period.

FOR RELIEF OF TENSION HEADACHE

The usual adult dosage is one or two capsules every four hours up to 8 capsules a day.
Desvenlafaxine Extended...

Desvenlafaxine Extended-release

2.1 General Instruction for Use

The recommended dose for Desvenlafaxine Extended-Release Tablets is 50 mg once daily, with or without food.

In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses.

When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.4  ) and Warnings and Precautions (5.7  )].

Desvenlafaxine Extended-Release Tablets should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.

2.2 Special Populations

Patients with renal impairment

The maximum recommended dose in patients with moderate renal impairment (24-hr creatinine clearance [CrCl] = 30 to 50 mL/min, Cockcroft-Gault [C-G]) is 50 mg per day. The maximum recommended dose in patients with severe renal impairment (24-hr CrCl less than 30 mL/min, C-G) or end-stage renal disease (ESRD) is 50 mg every other day. Supplemental doses should not be given to patients after dialysis [see Use in Specific Populations (8.6  ) and Clinical Pharmacology (12.3  .)].

Patients with hepatic impairment

The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended [see Clinical Pharmacology (12.3  )].

2.3 Maintenance/Continuation/Extended Treatment

It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be periodically reassessed to determine the need for continued treatment.

2.4 Discontinuing Desvenlafaxine Extended-Release Tablets

Symptoms associated with discontinuation of Desvenlafaxine Extended-Release Tablets, other SNRIs and SSRIs have been reported [see Warnings and Precautions (5.7  )]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.

2.5 Switching Patients From Other Antidepressants to Desvenlafaxine Extended-Release Tablets

Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to desvenlafaxine. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.

2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders

At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Desvenlafaxine Extended-Release Tablets. Conversely, at least 7 days should be allowed after stopping Desvenlafaxine Extended-Release Tablets before starting an MAOI intended to treat psychiatric disorders [see Contraindications (4 )].

Use of Desvenlafaxine Extended-Release Tablets with other MAOIs such as Linezolid or Methylene Blue

Do not start Desvenlafaxine Extended-Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see Contraindications (4 )] .

In some cases, a patient already receiving Desvenlafaxine Extended-Release Tablets therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, Desvenlafaxine Extended-Release Tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Desvenlafaxine Extended-Release Tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see Warnings and Precautions (5.2  )].

The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Desvenlafaxine Extended-Release Tablets is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see Warnings and Precautions (5.2  )].

Macoven Pharmaceuticals

Manufacturer Details

Share This Page

Macoven Pharmaceuticals Drugs